- ----------------------------------------------------------------------------
Potential Persons who are able to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
- -----------------------------------------------------------------------------
-----------------------
OMB APRROVAL
------------------------
OMB Number 3232-0060
------------------------
Expires: May 31, 2000
------------------------
Estimated average
burden hours
per response: 5
------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported): April 14, 2000
Diabetex International, Corp.
------------------------------------------------------------
(Exact Name of Registrant)
Nevada 000-30380 87-0458228
- ----------------------------- ------------------ -----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
7321 Roseville Road,Sacramento, CA 95482
- ------------------------------------- ------------------------
(Address of principal executive office) (Zip Code)
Registrant's Telephone number, including area code (702) 293-0909
--------------------------
--------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 1. CHANGES IN CONTROL OF REGISTRANT
There are no changes in the control of the Registrant.
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
There have been no acquisitons or dispositon of assets.
ITEM 3. BANKRUPTCY OR RECERVSHIP
The Company is not in bankruptcy or recervship.
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
The Company has not changed its Certifying Accountant.
ITEM 5. RESIGNATIONS OF REGISTRANT'S DIRECTORS
While none of the Directors of the Company have resigned or failed to stand
for reelection the following changes to the Board of Directors is reported
herein:
In addition to Philip Bloomquist as Director, Benjamin Brucker
Weisman, Ph.D is added to the Board.
Mr. Bloomquist continues as the Chairman of the Board and Dr.
Weisman will assume the duties of a director and Chief Executive Officer.
ITEM 6. FINANCIAL STATEMENTS AND EXHIBITS
No financial statements are included with this report.
Included as an Exhibit is a copy of the employment contract by and between Dr.
Weisman.
ITEM 7. CHANGES IN FISCAL YEAR
There has been no change to the Company's fiscal year.
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Diabetex International, Corp.
----------------------------------
Date: April 14, 2000 /s/ Philip Bloomquist
------------------------------------
Philip Bloomquist
Secretary